Weekend Edition: A Friendlier FDA, Russell 2000 To Soar, and the Yelp IPO

Weekend Edition:  A Friendlier FDA, Russell 2000 To Soar, and the Yelp IPO March 10, 2012 Here are the top investment ideas for the week: Friendlier FDA Making Biotech Investors Rich! Betting on biotechs with new drugs coming up for FDA approval may have just become the best game in town.  After a stingy 2010 in which only 21 new drugs gained regulatory approval, the FDA essentially opened the flood gates in 2011. You need to know about this guy... Who wouldn't want to be in a stock that starts out trading for a few bucks a share and then rockets up 100%, 200%, or even 1,000%?  If that's the kind of explosive returns you're looking for, then I'd like you to meet Gordon Lewis over at Penny Stock Research. A Cup And Handle You Don't Want To Miss But believe me, the pattern has a great track record of occurring just before a stock or index makes a big move higher.  Just flip through a few charts of some of the best performing stocks of all-time and you'll see this pattern over and over again. Dow 14,000?… You Bet As you know, this is an election year here in the US.  Couple that with an improving US economy, and you have a winning combination for stocks.  And now that Europe is finally getting back on track, the bullish situation improves even more. And from our friends at Penny Stock Research: Yelp IPO:  A Good Sign For Social Media Just last week, we saw the much anticipated IPO of Yelp (YELP).  The online city guide and review site is perhaps the second most anticipated internet IPO this year… behind only Facebook in popularity. Have a great weekend, John Alexander, Editor http://www.DynamicWealthReport.com Copyright 2012 Hyperion Financial Group, LLC.  All Rights Reserved.  Protected by copyright laws of the United States and international treaties. This email may only be used pursuant to the subscription agreement controlling use of the Dynamic Wealth Report website and any reproduction, copying, or redistribution of this email or its contents, in whole or in part, is strictly prohibited without the express written permission of Hyperion Financial Group, LLC. LEGAL DISCLAIMER: Neither Hyperion Financial Group LLC nor any of its employees are a registered investment advisor or a Broker/Dealer. As such, Hyperion Financial Group, LLC does not offer or provide personalized investment advice. Although Hyperion Financial Group, LLC employees may answer general customer service questions, they are not licensed under securities laws to address your particular investment situation. Nothing in this report, nor any communication by our employees to you should be considered personalized investment advice. Owners and writers may have positions in the securities that are discussed. However, no associated employees may intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. We accept no compensation from any companies mentioned in our reports. Past performance is no guarantee of future results. All information is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell any security. All opinions, analyses and information contained herein are based on sources believed to be reliable and written in good faith, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. Investments recommended in this publication should only be made after consulting with your financial advisor.

This message was sent to ignoble.experiment@arconati.us from: Hyperion Financial | 20701 N Scottsdale Rd, Ste 107-154 | Scottsdale, AZ 85255

Email Marketing by

Manage Your Subscription  |  Forward To a Friend